Emplicure Ab

Orexo Ab

Susanne Bredenberg

Håkan Engqvist

Anna Dahlgren

Anders Sågström

Anders Pettersson

Thomas Lundqvist

Christer Nystrom

Wei Xia

Christer Nyström

Anders Petterson

Bing Cai

Anders SÄGSTRÖM

Christer NYSTRÖM

A transdermal drug administration device comprising a drug delivery element () defining a contact surface () for location, in use, against a patient's skin. The drug delivery element () includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

Transdermal drug administration device

There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

Abuse resistant formula

There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterized in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.

There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.

Pharmaceutical formulations useful in the treatment of insomnia

Growing community of inventors

Uppsala, Sweden

Susanne Bredenberg